Eisai Co., Ltd.: Eisai Signs In-Licensing Agreement With Dainippon Pharmaceutical for Potential New Treatment for Diabetic Neuropathy
29th Sep 2005, 10:51 GMT
TOKYO (MARKET WIRE) Dainippon Pharmaceutical Co., Ltd (Headquarters: Osaka, President: Kenjiro Miyatake) and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) today signed an exclusive licensing agreement for AS-3201 (generic name: ranirestat), an investigational drug for the treatment of diabetic neuropathy that was discovered and is being developed by Dainippon Pharmaceutical. Under the agreement, Eisai will
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech